
Robert M. Kunemund
Examiner (ID: 17318)
| Most Active Art Unit | 1714 |
| Art Unit(s) | 1792, 1107, 1103, 1109, 1765, 1722, 1714, 1763 |
| Total Applications | 3570 |
| Issued Applications | 2787 |
| Pending Applications | 196 |
| Abandoned Applications | 616 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 19641437
[patent_doc_number] => 20240415957
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-12-19
[patent_title] => PRO-INFLAMMATORY AND ANTI-CANCER FUNCTIONS OF TOLL-LIKE RECEPTOR 4 ANTAGONISTS
[patent_app_type] => utility
[patent_app_number] => 18/746749
[patent_app_country] => US
[patent_app_date] => 2024-06-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23338
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18746749
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/746749 | PRO-INFLAMMATORY AND ANTI-CANCER FUNCTIONS OF TOLL-LIKE RECEPTOR 4 ANTAGONISTS | Jun 17, 2024 | Pending |
Array
(
[id] => 19497684
[patent_doc_number] => 20240336702
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-10
[patent_title] => BISPECIFIC ANTIBODIES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/743295
[patent_app_country] => US
[patent_app_date] => 2024-06-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27487
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -52
[patent_words_short_claim] => 86
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18743295
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/743295 | BISPECIFIC ANTIBODIES AND USES THEREOF | Jun 13, 2024 | Abandoned |
Array
(
[id] => 19724101
[patent_doc_number] => 20250026852
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-01-23
[patent_title] => POLYPEPTIDE INCLUDING ANTIGEN-BINDING DOMAIN AND CARRYING SECTION
[patent_app_type] => utility
[patent_app_number] => 18/672417
[patent_app_country] => US
[patent_app_date] => 2024-05-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 69109
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18672417
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/672417 | POLYPEPTIDE INCLUDING ANTIGEN-BINDING DOMAIN AND CARRYING SECTION | May 22, 2024 | Pending |
Array
(
[id] => 19541738
[patent_doc_number] => 20240358774
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-31
[patent_title] => USE OF MICROBIOME IN THE FIELD OF MICROBIALS AND THERAPEUTICS
[patent_app_type] => utility
[patent_app_number] => 18/646922
[patent_app_country] => US
[patent_app_date] => 2024-04-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4206
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 66
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18646922
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/646922 | USE OF MICROBIOME IN THE FIELD OF MICROBIALS AND THERAPEUTICS | Apr 25, 2024 | Pending |
Array
(
[id] => 19448978
[patent_doc_number] => 20240309108
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-19
[patent_title] => ANTIBODIES AGAINST CLAUDIN 18.2 USEFUL IN CANCER DIAGNOSIS
[patent_app_type] => utility
[patent_app_number] => 18/625004
[patent_app_country] => US
[patent_app_date] => 2024-04-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22928
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 17
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18625004
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/625004 | ANTIBODIES AGAINST CLAUDIN 18.2 USEFUL IN CANCER DIAGNOSIS | Apr 1, 2024 | Pending |
Array
(
[id] => 19477451
[patent_doc_number] => 20240325493
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-03
[patent_title] => REGULATOR OF TUMOR CELL FUNCTIONS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/623995
[patent_app_country] => US
[patent_app_date] => 2024-04-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20386
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 34
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18623995
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/623995 | REGULATOR OF TUMOR CELL FUNCTIONS AND USES THEREOF | Mar 31, 2024 | Pending |
Array
(
[id] => 19512143
[patent_doc_number] => 20240343829
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-17
[patent_title] => ANTI-PLASMA KALLIKREIN ANTIBODY DOSING REGIMENS FOR TREATING HEREDITARY ANGIOEDEMA
[patent_app_type] => utility
[patent_app_number] => 18/615934
[patent_app_country] => US
[patent_app_date] => 2024-03-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 60484
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18615934
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/615934 | ANTI-PLASMA KALLIKREIN ANTIBODY DOSING REGIMENS FOR TREATING HEREDITARY ANGIOEDEMA | Mar 24, 2024 | Pending |
Array
(
[id] => 19557761
[patent_doc_number] => 20240369553
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-07
[patent_title] => BIOMARKERS FOR EARLY DIAGNOSIS AND DIFFERENTIATION OF MYCOBACTERIAL INFECTION
[patent_app_type] => utility
[patent_app_number] => 18/599008
[patent_app_country] => US
[patent_app_date] => 2024-03-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10178
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 100
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18599008
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/599008 | BIOMARKERS FOR EARLY DIAGNOSIS AND DIFFERENTIATION OF MYCOBACTERIAL INFECTION | Mar 6, 2024 | Pending |
Array
(
[id] => 19571894
[patent_doc_number] => 20240376186
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-14
[patent_title] => C3b-Binding Fusion Proteins
[patent_app_type] => utility
[patent_app_number] => 18/588440
[patent_app_country] => US
[patent_app_date] => 2024-02-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30245
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18588440
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/588440 | C3b-Binding Fusion Proteins | Feb 26, 2024 | Pending |
Array
(
[id] => 19745686
[patent_doc_number] => 20250034251
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-01-30
[patent_title] => ANTIBODY CHEMICALLY INDUCED DIMERIZER (ABCID) AS MOLECULAR SWITCHES FOR REGULATING CELLULAR THERAPIES
[patent_app_type] => utility
[patent_app_number] => 18/437999
[patent_app_country] => US
[patent_app_date] => 2024-02-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 57527
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -38
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18437999
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/437999 | ANTIBODY CHEMICALLY INDUCED DIMERIZER (ABCID) AS MOLECULAR SWITCHES FOR REGULATING CELLULAR THERAPIES | Feb 8, 2024 | Pending |
Array
(
[id] => 19479485
[patent_doc_number] => 20240327527
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-03
[patent_title] => ACTIVATABLE ANTIBODIES AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/436554
[patent_app_country] => US
[patent_app_date] => 2024-02-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 36101
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18436554
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/436554 | ACTIVATABLE ANTIBODIES AND METHODS OF USE THEREOF | Feb 7, 2024 | Pending |
Array
(
[id] => 19359306
[patent_doc_number] => 20240261340
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-08
[patent_title] => Cutibacterium Acnes Biomimetic, Prebiotic, Probiotic and Postbiotic Compositions for Treatment of Skin Conditions
[patent_app_type] => utility
[patent_app_number] => 18/429870
[patent_app_country] => US
[patent_app_date] => 2024-02-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5595
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 44
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18429870
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/429870 | Cutibacterium Acnes Biomimetic, Prebiotic, Probiotic and Postbiotic Compositions for Treatment of Skin Conditions | Jan 31, 2024 | Pending |
Array
(
[id] => 19586419
[patent_doc_number] => 20240383976
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-21
[patent_title] => MANUFACTURING METHODS FOR PRODUCING ANTI-IL12/IL23 ANTIBODY COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 18/427000
[patent_app_country] => US
[patent_app_date] => 2024-01-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31833
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18427000
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/427000 | MANUFACTURING METHODS FOR PRODUCING ANTI-IL12/IL23 ANTIBODY COMPOSITIONS | Jan 29, 2024 | Pending |
Array
(
[id] => 19217869
[patent_doc_number] => 20240182573
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-06
[patent_title] => STABLE FORMULATIONS OF ANTI-TIGIT ANTIBODIES ALONE AND IN COMBINATION WITH PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/422352
[patent_app_country] => US
[patent_app_date] => 2024-01-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30372
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18422352
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/422352 | STABLE FORMULATIONS OF ANTI-TIGIT ANTIBODIES ALONE AND IN COMBINATION WITH PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF | Jan 24, 2024 | Abandoned |
Array
(
[id] => 19691272
[patent_doc_number] => 20250009817
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-01-09
[patent_title] => IMMUNOMODULATING COMPOSITION CONTAINING GASSERI
[patent_app_type] => utility
[patent_app_number] => 18/417720
[patent_app_country] => US
[patent_app_date] => 2024-01-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6896
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 39
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18417720
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/417720 | IMMUNOMODULATING COMPOSITION CONTAINING GASSERI | Jan 18, 2024 | Pending |
Array
(
[id] => 19800551
[patent_doc_number] => 20250066476
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-02-27
[patent_title] => MULTISPECIFIC HEAVY CHAIN ANTIBODIES WITH MODIFIED HEAVY CHAIN CONSTANT REGIONS
[patent_app_type] => utility
[patent_app_number] => 18/393099
[patent_app_country] => US
[patent_app_date] => 2023-12-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30759
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18393099
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/393099 | MULTISPECIFIC HEAVY CHAIN ANTIBODIES WITH MODIFIED HEAVY CHAIN CONSTANT REGIONS | Dec 20, 2023 | Abandoned |
Array
(
[id] => 19448975
[patent_doc_number] => 20240309105
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-19
[patent_title] => ANTI-CD40 ANTIBODIES FOR USE IN TREATING AUTOIMMUNE DISEASE
[patent_app_type] => utility
[patent_app_number] => 18/543162
[patent_app_country] => US
[patent_app_date] => 2023-12-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38353
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18543162
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/543162 | ANTI-CD40 ANTIBODIES FOR USE IN TREATING AUTOIMMUNE DISEASE | Dec 17, 2023 | Pending |
Array
(
[id] => 19050937
[patent_doc_number] => 20240092906
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-21
[patent_title] => BISPECIFIC ANTIGEN-BINDING MOLECULES AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 18/517327
[patent_app_country] => US
[patent_app_date] => 2023-11-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 66544
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -230
[patent_words_short_claim] => 139
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18517327
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/517327 | Bispecific antigen-binding molecules and methods of use | Nov 21, 2023 | Issued |
Array
(
[id] => 19018952
[patent_doc_number] => 20240075123
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-07
[patent_title] => TREATMENT OF CANCERS AND INFECTIOUS DISEASES WITH KILLED INTACT BACTERIA
[patent_app_type] => utility
[patent_app_number] => 18/497286
[patent_app_country] => US
[patent_app_date] => 2023-10-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27494
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 82
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18497286
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/497286 | TREATMENT OF CANCERS AND INFECTIOUS DISEASES WITH KILLED INTACT BACTERIA | Oct 29, 2023 | Pending |
Array
(
[id] => 19032559
[patent_doc_number] => 20240082374
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-14
[patent_title] => Cancer Vaccines and Methods of Treatment Using The Same
[patent_app_type] => utility
[patent_app_number] => 18/472640
[patent_app_country] => US
[patent_app_date] => 2023-09-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21576
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -3
[patent_words_short_claim] => 13
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18472640
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/472640 | Cancer Vaccines and Methods of Treatment Using The Same | Sep 21, 2023 | Abandoned |